NervGen (NGEN) Stock Price Target Cut to $15 Due to Dilution
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowH.C. Wainwright has reduced the stock price target for NervGen Pharma (NGEN) to $15. This adjustment reflects concerns over share dilution affecting the company's market valuation. Investors may perceive this downward revision as a sign of potential challenges for NervGen in maintaining stock price stability. The decrease in the target price could impact investor confidence and trading volumes going forward.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
